Nektar Therapeutics Announces 2024 Annual Meeting of Stockholders on June 5
Ticker: NKTR · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 906709
Sentiment: neutral
Topics: Nektar Therapeutics, Annual Meeting, Proxy Statement, Executive Compensation, Stockholder Vote
TL;DR
<b>Nektar Therapeutics will host its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on director elections, equity plan amendments, auditor ratification, and executive compensation.</b>
AI Summary
NEKTAR THERAPEUTICS (NKTR) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Nektar Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 2:00 p.m. Pacific Time via live webcast. The meeting agenda includes the election of three directors, approval of an amendment to the 2017 Performance Incentive Plan to increase share authorization by 8,000,000 shares, and ratification of Ernst & Young LLP as independent auditor. Stockholders will also vote on a non-binding advisory resolution regarding executive compensation ('say-on-pay'). The record date for determining stockholders entitled to vote is April 8, 2024. The meeting will be conducted by remote communication, with participation via www.virtualshareholdermeeting.com/NKTR2024.
Why It Matters
For investors and stakeholders tracking NEKTAR THERAPEUTICS, this filing contains several important signals. The proposed amendment to the 2017 Performance Incentive Plan seeks to increase the number of authorized shares, which could impact future equity dilution for existing shareholders. The 'say-on-pay' vote provides stockholders with an advisory opinion on the company's executive compensation practices, potentially influencing future compensation decisions.
Risk Assessment
Risk Level: low — NEKTAR THERAPEUTICS shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
Analyst Insight
Stockholders should review the proposals regarding director elections, the equity incentive plan amendment, and executive compensation before the June 5th meeting.
Key Numbers
- June 5, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 2:00 p.m. Pacific Time — Meeting Time (2024 Annual Meeting of Stockholders)
- April 8, 2024 — Record Date (For determining stockholders entitled to vote)
- 3 — Directors to be Elected (To be elected at the meeting)
- 8,000,000 — Additional Shares (For the 2017 Performance Incentive Plan)
Key Players & Entities
- Nektar Therapeutics (company) — Registrant name
- June 5, 2024 (date) — Date of Annual Meeting
- April 8, 2024 (date) — Record date for Annual Meeting
- Ernst & Young LLP (company) — Independent registered public accounting firm
- 2017 Performance Incentive Plan (plan) — Plan to be amended
- 8,000,000 (dollar_amount) — Shares to be added to incentive plan
FAQ
When did NEKTAR THERAPEUTICS file this DEF 14A?
NEKTAR THERAPEUTICS filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NEKTAR THERAPEUTICS (NKTR).
Where can I read the original DEF 14A filing from NEKTAR THERAPEUTICS?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NEKTAR THERAPEUTICS.
What are the key takeaways from NEKTAR THERAPEUTICS's DEF 14A?
NEKTAR THERAPEUTICS filed this DEF 14A on April 26, 2024. Key takeaways: Nektar Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 2:00 p.m. Pacific Time via live webcast.. The meeting agenda includes the election of three directors, approval of an amendment to the 2017 Performance Incentive Plan to increase share authorization by 8,000,000 shares, and ratification of Ernst & Young LLP as independent auditor.. Stockholders will also vote on a non-binding advisory resolution regarding executive compensation ('say-on-pay')..
Is NEKTAR THERAPEUTICS a risky investment based on this filing?
Based on this DEF 14A, NEKTAR THERAPEUTICS presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
What should investors do after reading NEKTAR THERAPEUTICS's DEF 14A?
Stockholders should review the proposals regarding director elections, the equity incentive plan amendment, and executive compensation before the June 5th meeting. The overall sentiment from this filing is neutral.
How does NEKTAR THERAPEUTICS compare to its industry peers?
Nektar Therapeutics operates in the pharmaceutical preparations industry, focusing on developing innovative medicines.
Are there regulatory concerns for NEKTAR THERAPEUTICS?
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring specific disclosures for shareholder meetings.
Industry Context
Nektar Therapeutics operates in the pharmaceutical preparations industry, focusing on developing innovative medicines.
Regulatory Implications
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring specific disclosures for shareholder meetings.
What Investors Should Do
- Review the biographies and qualifications of the three director nominees.
- Understand the implications of increasing the share authorization under the 2017 Performance Incentive Plan.
- Evaluate the company's executive compensation practices ahead of the 'say-on-pay' advisory vote.
Key Dates
- 2024-06-05: Annual Meeting of Stockholders — Key date for voting on proposals
- 2024-04-08: Record Date — Determines eligibility to vote at the Annual Meeting
Year-Over-Year Comparison
This filing is a DEF 14A proxy statement for the 2024 Annual Meeting, providing details on upcoming shareholder votes and company governance.
Filing Stats: 4,936 words · 20 min read · ~16 pages · Grade level 12.1 · Accepted 2024-04-26 16:08:35
Key Financial Figures
- $15,500 — to pay Georgeson a fee of approximately $15,500 plus customary costs and expenses for t
Filing Documents
- ny20022201x1_def14a.htm (DEF 14A) — 1772KB
- logo_nektar.jpg (GRAPHIC) — 14KB
- ny20022201x1_barchart01.jpg (GRAPHIC) — 172KB
- ny20022201x1_pvp01.jpg (GRAPHIC) — 156KB
- ny20022201x1_pvp02.jpg (GRAPHIC) — 154KB
- ny20022201x1_pvp03.jpg (GRAPHIC) — 160KB
- ny20022201x1-pc_1.jpg (GRAPHIC) — 591KB
- ny20022201x1-pc_2.jpg (GRAPHIC) — 582KB
- 0001140361-24-022440.txt ( ) — 7276KB
- nktr-20240605.xsd (EX-101.SCH) — 5KB
- nktr-20240605_def.xml (EX-101.DEF) — 5KB
- nktr-20240605_lab.xml (EX-101.LAB) — 10KB
- nktr-20240605_pre.xml (EX-101.PRE) — 5KB
- ny20022201x1_def14a_htm.xml (XML) — 211KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 21 INFORMATION ABOUT THE BOARD OF DIRECTORS 22 THE BOARD OF DIRECTORS 22 DIRECTORS CONTINUING IN OFFICE UNTIL THE 2025 ANNUAL MEETING 22 DIRECTORS CONTINUING IN OFFICE UNTIL THE 2026 ANNUAL MEETING 22 CURRENT DIRECTORS NOMINATED FOR REELECTION TO SERVE UNTIL THE 2027 ANNUAL MEETING 23 MEETINGS OF THE BOARD OF DIRECTORS 24 CORPORATE GOVERNANCE 24 BOARD LEADERSHIP STRUCTURE 24 RISK OVERSIGHT 25 INDEPENDENCE OF THE BOARD OF DIRECTORS 26 INFORMATION REGARDING THE COMMITTEES OF THE BOARD OF DIRECTORS 27 STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS 33 CODE OF BUSINESS CONDUCT AND ETHICS 33 ORGANIZATION AND COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION 34 DIRECTOR COMPENSATION TABLE—FISCAL 2023 35 COMPENSATION DISCUSSION AND ANALYSIS 37 COMPENSATION COMMITTEE REPORT 58 SUMMARY COMPENSATION TABLE—FISCAL 2021-2023 59 DESCRIPTION OF EMPLOYMENT AGREEMENTS 60 GRANTS OF PLAN BASED AWARDS IN 2023 61 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END FOR 2023 64 OPTION EXERCISES AND STOCK VESTED IN 2023 66 POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL 66 PAY VERSUS PERFORMANCE 71 INFORMATION ABOUT OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 75 PRE-APPROVAL POLICIES AND PROCEDURES 75 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 76 OTHER MATTERS 77 ADDITIONAL INFORMATION 77 TABLE OF CONTENTS NEKTAR THERAPEUTICS 455 Mission Bay Boulevard South San Francisco, California 94158 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON June 5, 2024 AT 2:00 P.M. PACIFIC TIME QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING PROCEDURES For the convenience of our stockholders, we have elected to hold the 2024 Annual Meeting of Stockholders solely by means of remote communication. WHY AM I RECEIVING THESE MATERIALS?